Eric S. Schafer

879 total citations
36 papers, 391 citations indexed

About

Eric S. Schafer is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Eric S. Schafer has authored 36 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Public Health, Environmental and Occupational Health, 15 papers in Pediatrics, Perinatology and Child Health and 13 papers in Oncology. Recurrent topics in Eric S. Schafer's work include Acute Lymphoblastic Leukemia research (25 papers), Childhood Cancer Survivors' Quality of Life (15 papers) and Neutropenia and Cancer Infections (6 papers). Eric S. Schafer is often cited by papers focused on Acute Lymphoblastic Leukemia research (25 papers), Childhood Cancer Survivors' Quality of Life (15 papers) and Neutropenia and Cancer Infections (6 papers). Eric S. Schafer collaborates with scholars based in United States, Australia and United Kingdom. Eric S. Schafer's co-authors include Stephen P. Hunger, M. Brooke Bernhardt, Julienne Brackett, María E. Figueroa, Ari Melnick, Sandeep Negi, Emily McIntyre, Rafael A. Irizarry, Patrick A. Brown and Donald Small and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Eric S. Schafer

33 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric S. Schafer United States	11	200	159	115	95	92	36	391
Ci Pan China	14	157 0.8×	109 0.7×	70 0.6×	96 1.0×	107 1.2×	37	405
Ulrika Norén‐Nyström Sweden	13	413 2.1×	268 1.7×	148 1.3×	284 3.0×	95 1.0×	36	619
Sharon Bergeron United States	8	152 0.8×	80 0.5×	60 0.5×	57 0.6×	71 0.8×	10	291
ZoAnn E. Dreyer United States	7	138 0.7×	132 0.8×	50 0.4×	41 0.4×	57 0.6×	8	276
Katalin Csordás Hungary	11	159 0.8×	103 0.6×	53 0.5×	76 0.8×	86 0.9×	21	329
Jaime Estrada United States	9	104 0.5×	115 0.7×	54 0.5×	82 0.9×	74 0.8×	14	343
Marion Strullu France	11	88 0.4×	68 0.4×	50 0.4×	84 0.9×	61 0.7×	29	277
Per Bernell Sweden	15	190 0.9×	112 0.7×	133 1.2×	336 3.5×	97 1.1×	27	523
Elva Jiménez‐Hernández Mexico	10	105 0.5×	68 0.4×	95 0.8×	79 0.8×	95 1.0×	33	312
Maya Mahmoud United States	4	268 1.3×	128 0.8×	161 1.4×	248 2.6×	108 1.2×	7	546

Countries citing papers authored by Eric S. Schafer

Since Specialization

Citations

This map shows the geographic impact of Eric S. Schafer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric S. Schafer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric S. Schafer more than expected).

Fields of papers citing papers by Eric S. Schafer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric S. Schafer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric S. Schafer. The network helps show where Eric S. Schafer may publish in the future.

Co-authorship network of co-authors of Eric S. Schafer

This figure shows the co-authorship network connecting the top 25 collaborators of Eric S. Schafer. A scholar is included among the top collaborators of Eric S. Schafer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric S. Schafer. Eric S. Schafer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miller, Tamara P., Ethan A. Poweleit, Austin L. Brown, et al.. (2025). What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies. Pediatric Blood & Cancer. 72(7). e31744–e31744. 1 indexed citations

DeGroote, Nicholas P., Holly Lindsay, Eric S. Schafer, et al.. (2024). Toxicity profile of high‐dose methotrexate in young children with central nervous system tumors. Pediatric Blood & Cancer. 71(10). e31213–e31213.

Verma, Anupam, Yueh‐Yun Chi, Jemily Malvar, et al.. (2024). Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers. 16(3). 496–496. 6 indexed citations

Schafer, Eric S., Yueh‐Yun Chi, Jemily Malvar, et al.. (2023). Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Blood. 142(Supplement 1). 2872–2872.

Prudowsky, Zachary D., et al.. (2022). Sinusoidal Obstruction Syndrome of the Liver Associated With 6-Mercaptopurine During Maintenance in a Child With T-cell Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 45(1). e121–e123. 1 indexed citations

Schafer, Eric S., Alexandra M. Stevens, Eunji Jo, et al.. (2022). Real‐world experience in treating pediatric relapsed/refractory or therapy‐related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatric Blood & Cancer. 69(10). e29812–e29812. 7 indexed citations

Serrallach, Bettina L., Eric S. Schafer, Brandon Tran, et al.. (2022). Imaging Findings in Children Presenting with CNS Nelarabine Toxicity. American Journal of Neuroradiology. 43(12). 1802–1809. 1 indexed citations

Tasian, Sarah K., Lewis B. Silverman, James A. Whitlock, et al.. (2022). Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 107(10). 2295–2303. 11 indexed citations

Bernhardt, M. Brooke, et al.. (2020). Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage. Pediatric Blood & Cancer. 67(9). e28334–e28334. 7 indexed citations

10.

Ranch, Daniel, et al.. (2020). Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia. Leukemia & lymphoma. 61(11). 2771–2774. 6 indexed citations

11.

Grimes, Amanda B., Matthew B. Miller, M. Tarek Elghetany, Andrea N. Marcogliese, & Eric S. Schafer. (2020). A Case of a Very Young Child With T Lymphoblastic Lymphoma With Eosinophilia and PDGFRB Translocation: A Rare Form of Myeloid/Lymphoid Neoplasm Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB or FGFR1. Clinical Lymphoma Myeloma & Leukemia. 20(12). e990–e993. 1 indexed citations

12.

Schafer, Eric S., Rachel E. Rau, Stacey L. Berg, et al.. (2019). Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatric Blood & Cancer. 67(2). e28073–e28073. 52 indexed citations

13.

Schafer, Eric S., et al.. (2019). Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL). Leukemia & lymphoma. 61(5). 1246–1249. 8 indexed citations

14.

Foster, Jennifer H., Patrick A. Thompson, M. Brooke Bernhardt, et al.. (2018). A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemotherapy and Pharmacology. 83(2). 349–360. 16 indexed citations

15.

Schafer, Eric S., Rachel E. Rau, Stacey L. Berg, et al.. (2018). A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatric Blood & Cancer. 65(8). e27066–e27066. 14 indexed citations

16.

Brackett, Julienne, et al.. (2018). Prevention of mercaptopurine‐induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites. Pediatric Blood & Cancer. 66(4). e27577–e27577. 11 indexed citations

17.

Brackett, Julienne, et al.. (2017). Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification. Cancer Chemotherapy and Pharmacology. 80(6). 1261–1264. 10 indexed citations

18.

Brackett, Julienne, Eric S. Schafer, Daniel H. Leung, & M. Brooke Bernhardt. (2013). Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Pediatric Blood & Cancer. 61(6). 1114–1117. 26 indexed citations

19.

Schafer, Eric S. & Stephen P. Hunger. (2011). Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nature Reviews Clinical Oncology. 8(7). 417–424. 55 indexed citations

20.

Schafer, Eric S., Allen Chen, & R.J. Arceci. (2009). Sustained first remission in an adolescent with hepatosplenic T‐cell lymphoma treated with T‐cell leukemia induction, nucleoside analog‐based consolidation, and early hematopoietic stem cell transplant. Pediatric Blood & Cancer. 53(6). 1127–1129. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact